CTOR Rentabilitas operasi Citius Oncology, Inc.

Logo korporat perusahaan citiusonc.com (CTOR)

The operating margin metric demonstrates the efficiency dynamics of Citius Oncology, Inc. (CTOR), where -665.60 is the current value of the indicator. Citius Oncology, Inc. (CTOR) minimizes capital expenditures by outsourcing production and testing to external partners. Specialization in rare lymphatic pathologies and orphan drug status protect the niche from replication. Current revenue is generated by the market launch of a treatment for cutaneous T-cell lymphoma.

CTOR - Tingkat bathi operasi Citius Oncology ing rentang 14.08.2024 - 20.11.2026

Rincian analitis perusahaan Citius Oncology, Inc. (CTOR)

Analisis komprehensif perusahaan:CTOR, citiusonc.com
Barang utama Citius Oncology Inc

Operating margin reflects the share of profit from core operations relative to total revenue. This indicator measures cost management efficiency before accounting for taxes and debt obligations. For Citius Oncology, Inc. (CTOR), the absence of proprietary manufacturing plants and the outsourcing of trials minimize capital expenditures, directly impacting the calculation of this metric. The trend in operational efficiency allows for an assessment of the profitability of such a flexible business model. An increase in this indicator confirms the company's stability.

Pesaing Citius Oncology, Inc.

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|TuHURA Biosciences Inc. - Margin operasi|TARA - Margin operasi|FATE (Fate Therapeutics) - Margin dodolan operasi|Margin dodolan operasi Aadi Bioscience, Inc.|Margin dodolan operasi TCRX|Rentabilitas operasi CSBR|Margin operasi XBIT|Rentabilitas kegiatan operasi CEL-SCI Corp.|Rentabilitas operasi ostherapies.com OSTX|RADX: Rentabilitas dodolan miturut bathi operasi|ARTV: Margin dodolan operasi|ANL (Adlai Nortye) - Rentabilitas dodolan miturut bathi operasi|Veru (VERU) - Rentabilitas operasi|Margin dodolan operasi Tempest Therapeutics Inc|Rentabilitas operasi Xilio Therapeutics|Rentabilitas dodolan miturut bathi operasi RENB (Renovaro Inc.)|Rentabilitas operasi Mural Oncology PLC (MURA)|Margin operasi Kairos Pharma (KAPA)|Rentabilitas operasi onkuretherapeutics.com OKUR|GDTC: Rentabilitas dodolan miturut bathi operasi|CRIS: Margin dodolan operasi|apollomicsinc.com (APLM) - Margin dodolan operasi|THAR: Margin operasi|Margin dodolan operasi Advanced Biomed Inc.|Margin dodolan operasi GNPX|Rentabilitas dodolan miturut bathi operasi CLDI (Calidi Biotherapeutics)|Margin operasi SBFM|Xenetic Biosciences, Inc. - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Salarius Pharmaceuticals SLRX|Margin operasi purple-biotech.com PPBT|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi